Acceleron Pharma Inc. (XLRN) Has Broken Out To A New High On Study Results
Acceleron Pharma Inc. (XLRN) and Celgene (CELG) announced after the bell Thursday that the Phase 3 study of Luspatercept met its primary and key secondary endpoints.
Source: RTTNews